Rheumatoid arthritis patients who are given a combination of biologic agents run a higher risk for serious infection, but a study presented here revealed no new safety concerns for the pairing of rituximab (Rituxan) and other biologics in refractory patients.In the ongoing, open-label, phase II study that enrolled 176 patients, there were 17 serious adverse events (SAE) occurring in 14 people (8%), reported William Rigby, MD, of Dartmouth Medical School in Lebanon, N.H.
